AGL 38.78 Decreased By ▼ -0.72 (-1.82%)
AIRLINK 194.29 Increased By ▲ 17.66 (10%)
BOP 10.84 Increased By ▲ 0.75 (7.43%)
CNERGY 6.87 No Change ▼ 0.00 (0%)
DCL 10.19 Increased By ▲ 0.26 (2.62%)
DFML 43.13 Increased By ▲ 0.39 (0.91%)
DGKC 96.61 Decreased By ▼ -1.56 (-1.59%)
FCCL 38.07 Decreased By ▼ -1.24 (-3.15%)
FFBL 81.43 Decreased By ▼ -0.43 (-0.53%)
FFL 14.03 Decreased By ▼ -0.36 (-2.5%)
HUBC 118.98 Decreased By ▼ -2.46 (-2.03%)
HUMNL 14.77 Decreased By ▼ -0.57 (-3.72%)
KEL 5.74 Increased By ▲ 0.08 (1.41%)
KOSM 8.49 Increased By ▲ 0.37 (4.56%)
MLCF 46.54 Decreased By ▼ -1.57 (-3.26%)
NBP 77.23 Increased By ▲ 1.41 (1.86%)
OGDC 194.78 Decreased By ▼ -2.63 (-1.33%)
PAEL 34.74 Increased By ▲ 2.36 (7.29%)
PIBTL 8.38 Increased By ▲ 0.23 (2.82%)
PPL 174.57 Decreased By ▼ -0.93 (-0.53%)
PRL 33.17 Decreased By ▼ -0.92 (-2.7%)
PTC 24.57 Increased By ▲ 2.23 (9.98%)
SEARL 110.04 Increased By ▲ 6.84 (6.63%)
TELE 8.90 Increased By ▲ 0.39 (4.58%)
TOMCL 34.83 Decreased By ▼ -0.20 (-0.57%)
TPLP 11.69 Increased By ▲ 0.43 (3.82%)
TREET 18.56 Decreased By ▼ -0.59 (-3.08%)
TRG 60.06 Increased By ▲ 1.50 (2.56%)
UNITY 36.49 Increased By ▲ 1.63 (4.68%)
WTL 1.75 Increased By ▲ 0.16 (10.06%)
BR100 11,701 Increased By 49.8 (0.43%)
BR30 35,411 Decreased By -67.2 (-0.19%)
KSE100 109,054 Increased By 815 (0.75%)
KSE30 33,849 Increased By 155.6 (0.46%)

WASHINGTON: The administration of US President Joe Biden announced plans on Thursday to spend $3.2 billion to accelerate the development and discovery of antiviral treatments against Covid-19 and future threats.

The plan is called the Antiviral Program for Pandemics and its funding comes from the American Rescue Plan, a $1.9 trillion package passed by Congress in March.

"Antivirals are an important complement to existing vaccines, especially for individuals with certain conditions that might put them at a greater risk, for those whom vaccines may not be as protective," Anthony Fauci, the president's chief medical advisor on the pandemic, told reporters.

Antiviral medication can also act as an important line of defense against emerging variants of concern that evade the protective action of current generation vaccines, he added.

The plan will help accelerate clinical testing for oral antiviral pills currently under various stages of development, such as Merck's molnupiravir as well as efforts by Pfizer and Atea-Roche.

The plan is for these to be taken very early after an infection is confirmed, in order to stop the disease from progressing to the severe stage - mimicking what Tamiflu does for influenza. The other pillar of the program is seeding the discovery of new antivirals - not just against this coronavirus and its wider family, but other families of viruses that are believed to have pandemic potential.

Comments

Comments are closed.